(Q13896859)

Statements

instance of

type of chemical entity

0 references

subclass of

chemical compound

0 references

has use

medication

1 reference

title

Pembrolizumab (English)

stated in

DrugBank

language of work or name

English

publication date

17 November 2015

DrugBank ID

09037

image of molecular model or crystal lattice model

Pembrolizumab 5DK3.png
2,048 × 2,048; 211 KB

depicts

space-filling model

1 reference

imported from Wikimedia project

Russian Wikipedia

Wikimedia import URL

https://ru.wikipedia.org/?oldid=107323917

mass

149,000 dalton

1 reference

stated in

DrugBank

DrugBank ID

09037

active ingredient in

Keytruda

1 reference

European Medicines Agency product number

EMEA/H/C/003820

reference URL

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human_med_001886.jsp

retrieved

22 March 2017

World Health Organisation international non-proprietary name

pembrolizumab (English)

0 references

medical condition treated

colon cancer

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

transitional cell carcinoma

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

tongue squamous cell carcinoma

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

melanoma

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

bladder cancer

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

Merkel cell carcinoma

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

head and neck squamous cell carcinoma

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

bladder urothelial carcinoma

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

renal cell carcinoma

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

non-small-cell lung carcinoma

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

benign mesothelioma

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

squamous cell carcinoma of the lung

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

metastatic melanoma

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

physically interacts with

programmed cell death 1

subject has role

reaction inhibitor

1 reference

stated in

Open Targets Platform

retrieved

14 August 2023

reference URL

https://platform.opentargets.org/drug/CHEMBL3137343

route of administration

intravenous infusion and defusion

0 references

LiverTox likelihood score

LiverTox toxicity likelihood category E*

1 reference

stated in

LiverTox

retrieved

8 April 2021

reference URL

https://www.ncbi.nlm.nih.gov/books/n/livertox/Pembrolizumab

last update

1 May 2016

has characteristic

biopharmaceutical

1 reference

title

Pembrolizumab (English)

stated in

DrugBank

language of work or name

English

publication date

17 November 2015

DrugBank ID

09037

subject has role

immunological antineoplastic agent

1 reference

stated in

Medical Subject Headings

MeSH descriptor ID

C582435

retrieved

15 March 2018

monoclonal antibody

1 reference

stated in

DrugBank

DrugBank ID

09037

language of work or name

English

title

Pembrolizumab (English)

publication date

17 November 2015

Identifiers